Bank of Montreal Can increased its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 230,153 shares of the specialty pharmaceutical company's stock after purchasing an additional 8,257 shares during the quarter. Bank of Montreal Can owned approximately 1.09% of ANI Pharmaceuticals worth $12,723,000 as of its most recent SEC filing.
Other institutional investors have also added to or reduced their stakes in the company. US Bancorp DE boosted its stake in shares of ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after buying an additional 531 shares during the last quarter. KBC Group NV lifted its holdings in ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after acquiring an additional 600 shares during the period. KLP Kapitalforvaltning AS purchased a new position in ANI Pharmaceuticals in the fourth quarter worth $166,000. HighTower Advisors LLC purchased a new position in ANI Pharmaceuticals in the third quarter worth $222,000. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of ANI Pharmaceuticals by 10.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company's stock valued at $246,000 after purchasing an additional 412 shares during the last quarter. 76.05% of the stock is owned by institutional investors.
Analyst Ratings Changes
ANIP has been the topic of a number of research analyst reports. StockNews.com downgraded shares of ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Tuesday, April 8th. HC Wainwright reissued a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price target on the stock. Jefferies Financial Group started coverage on ANI Pharmaceuticals in a report on Friday, March 14th. They set a "buy" rating and a $80.00 price objective for the company. Finally, Guggenheim reissued a "buy" rating and issued a $86.00 target price on shares of ANI Pharmaceuticals in a research report on Friday. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $79.75.
View Our Latest Stock Report on ANIP
ANI Pharmaceuticals Stock Performance
Shares of NASDAQ:ANIP traded up $0.83 during trading on Tuesday, hitting $69.55. 191,896 shares of the company were exchanged, compared to its average volume of 269,229. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.00. The stock has a 50 day moving average of $62.71 and a 200 day moving average of $59.22. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The company has a market cap of $1.51 billion, a PE ratio of -126.45 and a beta of 0.49.
Insider Buying and Selling
In related news, VP Meredith Cook sold 400 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the transaction, the vice president now owns 80,545 shares of the company's stock, valued at approximately $5,100,914.85. The trade was a 0.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Krista Davis sold 1,000 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $60.86, for a total transaction of $60,860.00. Following the completion of the sale, the senior vice president now owns 66,525 shares in the company, valued at $4,048,711.50. This represents a 1.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 3,200 shares of company stock valued at $197,792. Corporate insiders own 12.70% of the company's stock.
About ANI Pharmaceuticals
(
Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Featured Stories
Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
